Get Started

Artificial Intelligence T-knife | Building Pipeline Of Innovative Therapeutics

Enterprise, Biotechnology, Therapeutic, Cancer Treatment, Molecular Biology, Clinical Research, Cell Therapy Berlin , Berlin , Germany

Artificial Intelligence

T-knife | Building Pipeline Of Innovative Therapeutics

Biotechnology, Therapeutic, Cancer Treatment, Molecular Biology, Clinical Research, Cell Therapy

Berlin , Berlin , Germany

We are a fast-growing, pre-clinical-stage biopharmaceutical company developing tumor-specific T cell receptor (TCR) therapies. Our dynamic, international team sets out with the ambitious goal to revolutionize the TCR landscape using our unique and proprietary transgenic HuTCR mouse platform to produce fully human TCRs for the treatment of cancer. To achieve this ambitious goal, we have successfully completed Series A financing with top-tier investors in August 2020.

Total Funding: $197.4 M

Funding Stage: Series B

Business Stage: Scaling Up

Market: B2B

Company Size: 51 to 100

Founded: 2018

Nov 2021

T-knife Appoints Laura Brege to its Board of Directors

Sep 2021

T-knife and Catalent Sign Technology Transfer and Manufacturing Agreement

Aug 2021

T-knife Raised $110M Series B Funding

Date

Round

$ Raised

Investors

08/02/2021

Series B

$110M

Versant Ventures, Sixty Degree Capital, RA Capital Management, Qatar Investment Authority, Andera Partners, LSP BioVentures, Fidelity, Casdin Capital, CaaS Capital

Date : 08/02/2021

Round: Series B

$ Raised: $110M

Investors: Versant Ventures, Sixty Degree Capital, RA Capital Management, Qatar Investment Authority, Andera Partners, LSP BioVentures, Fidelity, Casdin Capital, CaaS Capital

For AI/ML Startup Founders

Get introduced to VC/PE/CVC investors

Signup and Get Started

For Investors at VC/PE firms

Get introduced to AI/ML Startup founders or founders at T-knife